

# Antibe Therapeutics Inc

08:35 06 May 2020

## Antibe Therapeutics names former FDA official Dr Joseph Stauffer as chief medical officer

Antibe Therapeutics Inc (CVE:ATE) (OTCQB:ATBPF) has named Dr Joseph Stauffer, an industry veteran who has worked for both the US government and the private sector, to the new role of chief medical officer (CMO).

An anesthesiologist, Dr Stauffer has served as CMO in public and private drug therapy companies for nearly 20 years, building teams of physicians, scientists, regulators and safety experts to drive clinical success for a number of chronic and acute pain assets.

Antibe said he will assume a leadership role in its clinical development strategy and its increasing engagement with global regulatory agencies and potential large-market partners.

### READ: Antibe Therapeutics expects results from Phase 2B study of pain drug ATB-346 within six weeks

"Joe's hands-on knowledge of drug development for both chronic and acute pain, and his stature in pharmaceutical and regulatory circles, made him our top choice as CMO," Antibe CEO Dan Legault said in a statement Wednesday.

"In particular, his commercial awareness and expertise in analgesic trial design will serve as a great asset as we shift our focus to late-stage clinical development and partnering opportunities for the large markets."

Following his medical training, Dr Stauffer practised frontline medicine for a decade, including eight years as a US Navy general practice physician.

He then joined the US Food and Drug Administration (FDA) as a medical review officer for anti-inflammatory and analgesic drugs, subsequently being recruited by Abbott Laboratories (NYSE:ABT) as global medical director.

Over the succeeding years, Dr Stauffer led clinical operations, regulatory and medical affairs teams at Alpharma and Ikaria, each of which was acquired in \$1.6 billion cash transactions. He was also instrumental in guiding the clinical development programs that underpinned equity raises totaling more than \$250 million for Cara Therapeutics Inc (NASDAQ:CARA), a developer of novel chemical entities to treat post-operative pain and chronic itch in Chronic Kidney Disease.


He is a founding member of the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials, which became an official public-private partnership among pharmaceutical companies, the FDA, the National Institutes of Health, academia and patient advocacy organizations across the US.

"The world is in desperate need of safer therapies for pain and inflammation," Dr Stauffer said. "Antibe represents one of the few truly novel platforms in the field, and I look forward to playing a role in navigating its drug pipeline through the

**Price:** 0.44

**Market Cap:** \$155.39 m

### 1 Year Share Price Graph



August 2019 February 2020 August 2020

### Share Information

**Code:** ATE

**Listing:** TSX-V

**52 week High Low**  
0.89 0.32

**Sector:** Pharma & Biotech

**Website:** antibethera.com

### Company Synopsis:

*Antibe Therapeutics is a publicly-traded biotechnology company pursuing a breakthrough advance in the treatment and prevention of inflammation. Antibe's drug pipeline addresses a \$20+ billion market in non-addictive pain management, cardiovascular disease, and cancer prevention.*

action@proactiveinvestors.com

later stages of clinical development, and ultimately providing patients with a safer treatment paradigm for pain management."

In connection with Dr Stauffer's appointment, the company has granted him a total of 500,000 restricted share units (RSUs). All RSUs are subject to time-based vesting; one-third of the RSUs granted will vest on each of the first, second and third anniversaries of today's date.

Antibe, based in Toronto, is currently developing ATB-346 as an alternative to nonsteroidal anti-inflammatory drugs, or NSAIDs. The company is now conducting a Phase 2 trial designed to validate ATB-346's effectiveness compared to placebo in reducing osteoarthritis pain.

Contact the author: [patrick@proactiveinvestors.com](mailto:patrick@proactiveinvestors.com)

Follow him on Twitter [@PatrickMGraham](https://twitter.com/PatrickMGraham)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).